2022 CSCO |Professor Wu Lingying: Promoting the Standardized Diagnosis and Treatment of Ovarian Cancer and Helping "Healthy China 2030"

preface

The 25th National Congress of Clinical Oncology and the 2022 CSCO Annual Conference were held
from November 5th to 12th.
The conference focuses on the clinical frontier of oncology, invites well-known experts and scholars at home and abroad to make wonderful progress reports or lectures, and strives to comprehensively and accurately reflect new concepts and new trends
in the field of clinical oncology.
On the occasion of this conference, Yimaitong specially invited Professor Wu Lingying from the Cancer Hospital of the Chinese Academy of Medical Sciences to share the standardized diagnosis and treatment of ovarian cancer and send a message
to young and middle-aged doctors.

Expert profiles

Professor Wu Lingying

• Chief physician, professor, doctoral supervisor

• Director of the Department of Gynecologic Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences

• Vice President of the Chinese Society of Clinical Oncology (CSCO).
  

• Chairman of the Gynecologic Oncology Expert Committee of the Chinese Society of Clinical Oncology (CSCO).
  

• Chairman of the Minimally Invasive Professional Committee for Women and Children of the China Maternal and Child Health Care Association

• Vice Chairman of the National Antitumor Drug Clinical Application Monitoring Committee

• Vice Chairman of the Clinical Research Expert Committee of the Chinese Society of Clinical Oncology

• Vice Chairman of the Gynecologic Oncology Professional Committee of the Chinese Anti-Cancer Association

• Vice Chairman of the Gynecologic Oncology Committee of the Beijing Branch of the Chinese Medical Association

• Standing Director of China Maternal and Child Health Care Association

Yimaitong: Ovarian cancer is one of the three major malignant tumors of the female reproductive system, can you briefly introduce the diagnosis and treatment status of ovarian cancer in China? What are your expectations for the standardized diagnosis and treatment and quality control of ovarian epithelial cancer in China?

Professor Wu Lingying

Cancer Hospital, Chinese Academy of Medical Sciences

Among the three major gynecological malignancies in China, the incidence rate is cervical cancer, followed by endometrial cancer, and the third is ovarian cancer, that is, the incidence of ovarian cancer is relatively low
.
However, due to its difficult early detection clinically, more than 70% of ovarian cancer patients are diagnosed in advanced stages, and the prognosis is poor, and it is easy to recur.

At present, although China vigorously promotes standardized diagnosis and treatment, due to the unbalanced economic development of various regions, the uneven level of clinicians' diagnosis and treatment, and the special circumstances such as differences in the division of labor in obstetrics and gynecology, medical oncology and surgery and other related departments in various hospitals in China, the current standardized diagnosis and treatment level of ovarian cancer in China is limited, and there may be many irregularities
in the clinical diagnosis and treatment process.
Big data analysis also shows that standardized diagnosis and treatment can greatly improve the efficacy of treatment, avoid unnecessary complications, and improve the quality of
life of patients.
Therefore, through the formulation of guidelines, training for these weak links, and improving the diagnosis and treatment level of doctors at all levels such as grassroots and young and middle-aged people, can bring good effects
to the further promotion of standardized diagnosis and treatment in China.
Under the guidance of the National Cancer Center and the National Cancer Quality Control Center, the Ovarian Cancer Single Disease Quality Control Expert Committee was established, and led by Professor Martin, experts participated in the formulation of ovarian cancer quality control evaluation standards, continuously promoted the optimization of the multidisciplinary diagnosis and treatment mode of ovarian cancer, and improved the planning of
diagnosis and treatment 。 It is hoped that through quality control from clinical diagnosis, molecular testing, preferred treatment, chemotherapy, maintenance therapy, treatment after relapse, surgery, drug selection, toxic side effects and other aspects, in order to better serve patients, in order to improve the efficacy, improve the five-year survival rate, and strive
for the goal of "Healthy China 2030".

In 2019, the guidelines for the diagnosis and treatment of ovarian epithelial cancer launched by the CSCO Gynecologic Oncology Expert Committee have become a powerful academic weapon
for the clinical diagnosis and treatment of ovarian cancer in China.
Could you please talk about the updates and highlights of this year's 2022 CSCO Ovarian Cancer Guidelines?

Professor Wu Lingying

Cancer Hospital, Chinese Academy of Medical Sciences

With the development of medical technology, the diagnosis and treatment technology of gynecological cancer is changing
with each passing day.
Especially in recent years, more and more research results
have been obtained in the fields of PARP inhibitors.
In the past, we recommended observational follow-up for patients who achieved complete remission after first-line chemotherapy, but now, at this year's ESMO conference, the seven-year overall survival (OS) results of the SOLO-1 study were released, suggesting that the olaparib group showed a significant survival benefit over the control group, and olaparib may be one of
the first-line maintenance treatment options for newly diagnosed ovarian cancer with BRCA mutations 。 In addition, the national multicenter PRIME study led by me reported detailed data from the phase III clinical study of niraparib as maintenance therapy at this year's SGO Annual Meeting, which confirmed that for newly diagnosed Chinese patients with advanced epithelial ovarian cancer, regardless of biomarker status, niraparib as maintenance therapy can significantly improve progression-free survival (PFS) after remission with platinum-containing chemotherapy and is tolerated
in safety.
While paying attention to the efficacy, we should also pay attention to the standardized application of drugs and their toxic side effects
.
Therefore, the guidelines also add content on the adverse effects of PARP inhibitors and their corresponding treatment
.
In addition, previous guidelines were mostly formulated for the diagnosis and treatment of ovarian epithelial cancer, and ovarian malignant tumors also included rare malignant germ cell tumors, sex cord stromal tumors, and borderline epithelial tumors
.
When this year's guidelines were formulated, they drew on the consensus of many experts and based on the results of high-level evidence-based medical research, and included these rare types of cancer diagnosis and treatment into the guidelines
.

In recent years, the "Voice of China" has gradually sung on the world stage, and the diagnosis and treatment level of gynecological tumors in China has gradually improved
.
Could you please bring some messages to young and middle-aged gynecological oncologists to help the diagnosis and treatment of gynecological oncology in China to the forefront of the world?

Professor Wu Lingying

Cancer Hospital, Chinese Academy of Medical Sciences

In recent years, many good achievements have been made in the field of gynecological oncology, and have gradually been recognized
by international peers.
This is mainly due to the rapid development of various fields related to our country, both in the economy and medicine, which gives us the opportunity to conduct relevant research
.
From participating in international multi-center research in the past, to later, we led the research ourselves, to now, we lead international multi-center research, more and more Chinese voices bloom on the international stage, providing better opportunities and higher platforms
for young and middle-aged doctors.
I believe that with their efforts, we will surely achieve more and better research results and be able to showcase our "Voice of China"
on the international stage.
As a backbone force, the future must belong to young and middle-aged doctors
.

Editor: Uni

Reviewer: Professor Wu Lingying

Typesetting: Uni

Execution: Uni

This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.